We analyzed genomic DNA from 40 colorectal cancer (CRC) and 24 non-small cell lung cancer (NSCLC) formalin-fixed paraffinembedded (FFPE) specimens using an assay that captures and sequences 2,574 coding exons representing 145 cancer-relevant genes (genes that are associated with cancer-related pathways, targeted therapy or prognosis), plus 37 introns from 14 genes that are frequently rearranged in cancer (Supplementary Table 1 ). We sequenced this 606,676-bp content, selected using solution phase hybridization, to an average coverage of 229×, with 84% of exons being sequenced at ≥100× coverage (Supplementary Table 2 and Supplementary Methods). To maximize mutation-detection sensitivity in heterogeneous cancer biopsies, we validated the test to detect base substitutions at a ≥10% mutant allele frequency with ≥99% sensitivity and to detect indels at a ≥20% mutant allele frequency with ≥95% sensitivity, with a false discovery rate of <1% (data not shown).
Among 40 CRCs, we identified 125 alterations in 21 genes. We found at least one alteration in 39 out of 40 tumors (with a range of 1-9 alterations), and 62.5% (25 out of 40) of the tumors harbored at least two classes of DNA alteration ( Fig. 1 and Supplementary Table 3 ). TP53 and APC were altered in 80% (32 out of 40) and 67.5% (27 out of 40) of CRCs, respectively, with both being mutated at higher frequencies than are reported in the Catalogue of Somatic Mutations in Cancer 1 . Additionally, 11 genes were mutated, amplified or rearranged in multiple CRCs: (2) and SMAD4 (2) . ALK, CDK8, LRP1B, MYC, MSH6, RICTOR, SMAD2 and STK11 were each altered in one tumor (Fig. 1a) . Notably, 52.5% of CRCs (21 out of 40) harbored at least one alteration that has been linked to a clinical treatment option or is currently being investigated in clinical trials of new targeted therapies. Examples of this include mutations in KRAS and BRAF (cetuximab 2,3 or panitumumab resistance 3 ), FBXW7 (anti-tubulin resistance 4 ), BRCA2 (poly-(ADP-ribose) polymerase (PARP) inhibitor trials 5 ), GNAS (MEK or ERK inhibitor trials 6 ) and PIK3CA (phosphoinositide-3-kinase, catalytic, alpha polypeptide (PI3K) and mechanistic target of rapamycin (mTOR) inhibitor trials 7 ) (Supplementary Table 4) .
We detected a fusion gene between C2orf44 and ALK in sequencing data from one subject with CRC ( Supplementary Fig. 1 ). This in-frame fusion starts at the canonical exon 20 recombination site that was previously reported for ALK gene fusions 8, 9 . C2orf44, on chromosome 2, contains a coiled-coil domain; the C2orf44-ALK fusion results from a 5,194,955-bp tandem duplication (Fig. 1b,c) . Complementary DNA (cDNA) sequencing identified 75 read pairs spanning the fusion junction (data not shown) and an 89.8-fold increase in 3′ ALK expression beginning at exon 20 relative to exons 1-19, suggesting that the C2orf44-ALK fusion transcript results in ALK kinase overexpression (Fig. 1d) . Immunohistochemistry (IHC) was negative for ALK staining (data not shown). Clinical detection of ALK rearrangements is currently performed using fluorescence in situ hybridization with ALK break-apart probes 9 or by RT-PCR using ALK-rearrangement-specific primers. Given the structure of this gene fusion, probably neither method would have detected it. These findings suggest that a previously unrecognized subset of individuals with CRC may harbor genetic alterations that may respond to treatment with crizotinib or other ALK inhibitors.
Among 24 NSCLCs, we identified 50 alterations in 21 genes, with at least one alteration being present in 83% (20 out of 24) of the tumors (with a range of 1-7 alterations). Twelve genes were altered in multiple tumors: (2) and ATM (2) . APC, CCNE1, CDK4, MLH1, MSH6, NF1, RB1, RET, and TSC1 were each altered in one tumor ( Fig. 2a and Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies Applying a next-generation sequencing assay targeting 145 cancer-relevant genes in 40 colorectal cancer and 24 non-small cell lung cancer formalin-fixed paraffin-embedded tissue specimens identified at least one clinically relevant genomic alteration in 59% of the samples and revealed two gene fusions, C2orf44-ALK in a colorectal cancer sample and KIF5B-RET in a lung adenocarcinoma. Further screening of 561 lung adenocarcinomas identified 11 additional tumors with KIF5B-RET gene fusions (2.0%; 95% CI 0.8-3.1%). Cells expressing oncogenic KIF5B-RET are sensitive to multi-kinase inhibitors that inhibit RET.
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. In 72% (36 out of 50) of the NSCLCs, at least one alteration was associated with a current clinical treatment or targeted therapy trial, including mutations in KRAS (epidermal growth factor receptor (EGFR) kinase inhibitor resistance 10 and PI3K
and MEK inhibitor trials 7 ), BRAF (v-raf murine sarcoma viral oncogene homolog B1 (BRAF) inhibitor trials, including those with vemurafenib 11 and GSK 2118436 (ref. 11)), EGFR (gefitinib or erlotinib sensitivity 12 ), MDM2 (nutlin trials 13 ), CDKN2A, CCNE1 and CDK4 SM91A3  SM92  SM86  SM51  SM90  SM44  SM48  SM53  SM114  SM96  SM93  SM87  SM89  SM71E  SM70E  SM107  SM63  SM109  SM64E  SM113  SM46  SM112  SM49A5E  SM55   3  3  3  3  3  3  2 2 2 2 1 1 1 1 1 1 1   1  2  2  2  2  2  2  2 Tubulin   KRAS  TP53  STK11  LRP1B  JAK2  CTNNB1  BRAF  PIK3CA  CDKN2A  ATM  EGFR  MDM2  NF1  RB1  APC  MLH1  MSH6  TSC1  CCNE1  CDK4 Number of alterations per sample 3 3 3 3   3   3 3 3 3 3 3 3 3 3 3 2   2  2  2 SM77E  SM12  SM98E  SM54  SM21  SM23  SM20  SM19  SM11  SM3  SM6  SM4  SM28  SM45  SM18  SM41E  SM7  SM32  SM81  SM88  SM100E  SM110E  SM39  SM40  SM75  SM67  SM29  SM36E  SM42E  SM83  SM73  SM74NE  SM16  SM14  SM61  SM13E  SM34 npg (cyclin-dependent kinase 4 (CDK4) inhibitor trials 14, 15 ) and PIK3CA (PI3K and mTOR inhibitor trials 7, 16 ) (Supplementary Table 4 ). In addition to the known NSCLC gene alterations, we made two notable discoveries. The first was a G1849T (V617F) JAK2 mutation present in three subjects at a low allele frequency (4-10%). Although commonly observed in myelodysplastic syndromes, this JAK2 mutation has not been described in solid tumors 1 . Sequencing additional NSCLCs will be required to characterize the role of JAK2 mutations in NSCLC, and clinical trials will be necessary to assess whether they predict sensitivity to JAK2 inhibitors 17 .
We also detected an 11,294,741-bp pericentric inversion on chromosome 10 generating a new gene fusion joining exons 1-15 of KIF5B to exons 12-20 of RET (Fig. 2b and Supplementary Fig. 2 ) in a lung adenocarcinoma from a 44-year-old, male 'never smoker' of European ancestry; this fusion is denoted K15;R12, based on the last KIF5B and first RET exons in the fusion. KIF5B exons 1-15 comprise the kinesin motor and coiled-coil domains that mediate homodimerization, whereas exon 15 is a known KIF5B-ALK fusion site in individuals with NSCLC 18 . RET exons 12-20 encode the tyrosine kinase portion of the PTC-RET fusions observed in ~35% of papillary thyroid carcinomas 19 (Fig. 2c) . cDNA sequencing identified 490 unique read pairs spanning the fusion junction (data not shown) and detected a 7.3-fold RET expression increase beginning at exon 12 relative to exons 1-11 (Fig. 2d) . IHC showed focal moderate cytoplasmic immunoreactivity for RET protein expression (Fig. 2e) .
An additional 117 NSCLCs (from 92 individuals of European ancestry, 5 African-American individuals and 20 individuals of unknown ancestry) screened by IHC showed moderate to intense RET staining in 22 samples. RT-PCR and cDNA sequencing of RNA from 15 tumors that had RET expression using IHC identified one additional KIF5B-RET fusion in a male former smoker of European ancestry (Supplementary Table 5) .
We evaluated tumors from 121 individuals of European ancestry and 405 Asians, comprising only never or limited former smokers, by RT-PCR for KIF5B-RET fusions, with 1 out of 121 (0.8%) Europeanancestry and 9 out of 405 (2%) Asian subjects testing positive for the fusion. None of the fusion-positive tumors contained mutations in EGFR, ERBB2, BRAF or KRAS or rearrangements of EML4-ALK or ROS1, resulting in a total of 10 individuals with RET rearrangements out of 159 (6.3%) subjects without previously known driver mutations (Supplementary Table 5 ). The lack of known oncogenic mutations in individuals positive for the KIF5B-RET fusion raises the possibility that the RET fusion is a driving oncogenic event. Of note, all additional 12 KIF5B-RET fusions (from the 11 individuals described above) were identified in lung adenocarcinomas, which comprised 561 of the 643 cases screened, in addition to the original 24 individuals, for an overall occurrence rate of 2.0% (95% CI 0.8-3.1%).
The 13 total RET fusions (from 12 individuals) comprise four unique transcripts: eight from K15;R12 (variant 1), three from K16;R12 (variant 2), one from K22;R12 (variant 3) and one from K15;R11 (variant 4) (the subject with variant 4 also had the K15;R12 variant) (Supplementary Figs. 2 and 3) . The KIF5B portions of the variants differ, but all retain the coiled-coil domain necessary for homodimerization. No identified RET fusion was amplified.
Thyroid cancers and cell lines harboring PTC-RET translocations are sensitive to sorafenib, which inhibits RET 20 , suggesting the KIF5B-RET gene fusion in NSCLC may be druggable. KIF5B-RET expression in Ba/F3 cells led to oncogenic transformation, as determined by interleukin-3 (IL-3)-independent growth. These cells were sensitive to sunitinib, sorafenib and vandetanib, which are all multi-targeted kinase inhibitors that inhibit RET but not gefitinib, which is an EGFR kinase inhibitor (Fig. 2f) . Sunitinib, but not gefitinib, inhibited RET phosphorylation in Ba/F3 cells with the KIF5B-RET fusion protein (Fig. 2g) . These findings suggest that RET kinase inhibitors should be tested in prospective clinical trials for therapeutic benefit in individuals with NSCLC that carry KIF5B-RET rearrangements.
Overall in this study, 52.5% of subjects with CRC and 71% of subjects with NSCLC had genomic alterations that were directly linked to a clinical therapeutic option, including two new gene fusions. Identifying even a small subpopulation of affected individuals with gene fusions who may be potentially responsive to targeted therapy, as exemplified by the discovery of C2orf44-ALK and KIF5B-RET, may have major therapeutic relevance, as highlighted by the recent US Food and Drug Administration's approval of crizotinib for the treatment of NSCLC that harbors rearrangements in ALK 9 . These findings in aggregate show the potentially large clinical impact of a single multiplex test that requires minimal DNA from FFPE tumor biopsies.
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Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturemedicine/.
Note: Supplementary information is available on the Nature Medicine website.
